First Turn Management LLC Increases Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

First Turn Management LLC increased its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 53.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 326,494 shares of the company's stock after purchasing an additional 113,550 shares during the period. Vera Therapeutics makes up about 2.3% of First Turn Management LLC's investment portfolio, making the stock its 23rd largest position. First Turn Management LLC owned about 0.60% of Vera Therapeutics worth $14,431,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Swiss National Bank lifted its stake in shares of Vera Therapeutics by 27.7% in the 1st quarter. Swiss National Bank now owns 62,200 shares of the company's stock valued at $2,682,000 after purchasing an additional 13,500 shares during the last quarter. Sei Investments Co. purchased a new position in Vera Therapeutics during the first quarter worth $479,000. Russell Investments Group Ltd. increased its position in Vera Therapeutics by 3,526.2% during the first quarter. Russell Investments Group Ltd. now owns 16,209 shares of the company's stock valued at $699,000 after acquiring an additional 15,762 shares during the last quarter. ProShare Advisors LLC bought a new stake in shares of Vera Therapeutics in the 1st quarter worth about $469,000. Finally, Vanguard Group Inc. boosted its stake in shares of Vera Therapeutics by 31.5% during the 1st quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company's stock worth $92,653,000 after purchasing an additional 515,106 shares during the period. Hedge funds and other institutional investors own 99.21% of the company's stock.

Vera Therapeutics Stock Up 2.4 %

Shares of Vera Therapeutics stock traded up $1.09 during trading on Tuesday, hitting $45.90. 537,474 shares of the stock traded hands, compared to its average volume of 909,449. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock's fifty day simple moving average is $42.70 and its 200 day simple moving average is $39.45. The firm has a market cap of $2.91 billion, a P/E ratio of -17.59 and a beta of 1.03. Vera Therapeutics, Inc. has a 52-week low of $12.28 and a 52-week high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.21). On average, equities analysts predict that Vera Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Beth C. Seidenberg sold 15,000 shares of the firm's stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $48.03, for a total value of $720,450.00. Following the sale, the director now directly owns 131,553 shares in the company, valued at approximately $6,318,490.59. This trade represents a 10.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marshall Fordyce sold 15,625 shares of the business's stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $37.50, for a total transaction of $585,937.50. Following the transaction, the chief executive officer now owns 307,972 shares of the company's stock, valued at approximately $11,548,950. This trade represents a 4.83 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 104,398 shares of company stock valued at $4,376,163 over the last 90 days. Corporate insiders own 21.70% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Evercore ISI raised shares of Vera Therapeutics to a "strong-buy" rating in a research report on Monday, September 16th. Guggenheim increased their price target on Vera Therapeutics from $56.00 to $64.00 and gave the stock a "buy" rating in a report on Monday, October 28th. Scotiabank began coverage on Vera Therapeutics in a report on Wednesday, October 16th. They set a "sector outperform" rating and a $60.00 price objective for the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $107.00 target price on shares of Vera Therapeutics in a research note on Tuesday, October 1st. Finally, Wedbush lifted their target price on Vera Therapeutics from $30.00 to $38.00 and gave the stock a "neutral" rating in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $57.88.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.